Evidence map›Paper›PMID 32556573›Full record

ArticleMikrochimica acta2020

Colorimetric nanoplatform for visual determination of cancer cells via target-catalyzed hairpin assembly actuated aggregation of gold nanoparticles.

Hadi Ravan, Akram Norouzi, Nima Sanadgol, Elyas Hosseinzadeh

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 17 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Hadi RavanDepartment of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran. ravan@uk.ac.ir.ORCID 0000-0001-8560-4900
Akram NorouziDepartment of Clinical Biochemistry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Nima SanadgolDepartment of Biology, Faculty of Sciences, University of Zabol, Zabol, Iran.
Elyas HosseinzadehSirjan School of Medical Sciences, Sirjan, Iran.
Kerman University of Medical Sciences · IRShahid Bahonar University of Kerman · IRSirjan University of Technology · IRZabol University · IR

Funding

Shahid Bahonar University of Kerman Not applicable
6 · The paper itself

Abstract

According to aptamer-mediated hairpin DNA cascade amplifier and gold nanoparticles aggregation, an optical platform for cancer cells determination has been proposed. High-affinity chimeric aptamers were used for cancer cell detection and also as an initiator for beginning hairpin assembly to construct three-way junction (3WJ) nanostructures. These three hairpins were modified at 3' ends with biotin. In the presence of target cell, chimeric aptamer binds to its ligand on cell surface and initiates 3WJ nanostructures formation. These 3WJ nanostructures interact with streptavidin-modified gold nanoparticles (AuNPs) via non-covalent biotin-streptavidin interactions and create a crossover lattice of nanoparticles. This event leads to AuNPs aggregation and red-shifting. The results were confirmed by gel electrophoresis and UV-visible spectrophotometry. The dynamic range of this assay is 25 to 10

Indexed as

Aptamers, NucleotideBiotinCell CountCell Line, TumorColorimetryDNAGoldHumansInverted Repeat SequencesLimit of DetectionMetal NanoparticlesStreptavidinAptamers, NucleotideBiotinDNAGoldStreptavidinAptamerCancer cell detectionColorimetryDNA circuitDNA nanotechnologyEnzyme-free signal amplificationGold nanoparticlesHairpin DNA cascade amplifierThree-way junctionToehold-mediated DNA strand displacement

Identifiers

PMID32556573
OpenAlexW3036648976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.